John Rinn, professor at the University of Colorado and co-founder of Lincswitch Therapeutics, on exploring long non-coding RNA.

Ep180: John Rinn on Discovering Drugs Based on Long Non-Coding RNA

"The Long Run"

Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. 

Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.

www.linkedin.com/in/grawoig/
twitter.com/grawoig
www.facebook.com/grawoig
www.instagram.com/grawoig/
www.researchgate.net/profile/David_Grawoig
www.youtube.com/channel/UCfgPyru4WcanipdpUq-m-DQ

Ep180: John Rinn on Discovering Drugs Based on Long Non-Coding RNA

The Long Run with Luke Timmerman